Risk of recurarization during retransfusion of autologous blood withdrawn after injection of muscle relaxants: A comparison of rocuronium and mivacurium.
Important information concerning the risk of recurarization when mivacurium and rocuronium have been administered prior to the removal of autologous blood in ANH. The anesthetist should be aware of this possibility when autologous blood is retransfused. – Konrad Messmer
This is an overview on the mechanism of action of rFVIIa and its role in hemostasis. rFVIIa directly activates FX, increases thrombin activation on activated platelets, and leads to generation of strong fibrin clot which is more resistant to fibrinolysis. rFVIIa exerts its action by interacting with tissue factor, but this group showed that high […]
Very good overview of the current situation. – V. Kretschmer
Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency.
After using rFVIIa effectively in the treatment of hemophilia patients with inhibitors against factors VIII and IX, this case report illustrates its efficacy in treating a 62-year-old woman with high titer inhibitor against factor XI. The patient received FXI:C to successfully cover several previous surgical procedures, however on this occasion the level of FXI inhibitor […]
This a thorough and comprehensive review on the mechanism of action and various indications and uses of rFVIIa, highlighting the pivotal role of factor VII in hemostasis, as well as the efficacy and safety of rFVIIa. – M. Aldouri.
Growing evidence shows that transfusion of stored red cells may well harm patients. Studies are therefore necessary in order to help establish the reasons for this negative effect. Decrease of deformability of red cells during storage may be one explanation. Reduced perfusion of the capillary bed may be the consequence of reduced deformability of red […]
This survey reflects the current situation in England and North Wales, where the prevailing opinion is that only the use of blood components is state of the art. There is decreasing need of source plasma for the industrial production of plasma derivatives due to recombinant products. England cannot use the plasma due to fear of […]
The article gives data on transfusion reactions that are not conclusive. There is no doubt about the reduction of non-hemolytic transfusion reactions in chronically transfused patients when using leukodepleted cellular blood components. Finding no difference in the incidence of transfusion reactions between leukodepleted and non-leukodepleted RBCs is contrary to daily experience. However, it is true […]